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Abstract
Benzodiazepines are commonly prescribed to patients with schizophrenia in many countries, but as little
is known about such treatment in Asia, we evaluated their adjunctive use for 6761 in-patients diagnosed
with schizophrenia in nine Asian countries using a cross-sectional study design in 2001, 2004 and 2008.
Multivariate logistic regression and multivariate linear regression analyses were performed to assess
predictors of benzodiazepine use and dose, respectively. Overall, 54% of the patients received adjunctive
benzodiazepines at an average daily dose equivalent to 30.3 mg diazepam, with minor changes over the
years sampled. Benzodiazepine use was highest in Taiwan and Japan, lowest in Thailand and China, and
was associated with fewer years ill, presence of delusions (OR 1.24), hallucinations (OR 1.22), disorganized
speech (OR 1.17), social or occupational dysfunction (OR 1.16), and use of mood stabilizers (OR 3.15),
antiparkinsonian (OR 1.79) or antidepressant drugs (OR 1.33), and lower doses of antipsychotics
(all p=0.016 to <0.001). Benzodiazepine doses were highest in Taiwan and China, lowest in Korea
and Singapore ; higher doses were associated with being young, male, physically aggressive, receiving
mood stabilizers, and having electroconvulsive treatment (all p=0.019 to <0.001). Benzodiazepine use
was associated with neurological and systemic adverse effects. In conclusion, benzodiazepine use was
common in Asian patients with schizophrenia. Predictors of benzodiazepine use and dose differed in this
population. Critical clinical guidelines should be developed specifically for Asian countries to address
sound practices in regard to use of benzodiazepines for psychotic disorders.
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Introduction
Benzodiazepines have hypnotic, anxiolytic, anticon-
vulsant, myorelaxant and amnestic properties that are
useful for a wide range of conditions. Their main
clinical indications are for anxiety and sleep disorders
(Ashton, 1994b), although they are also commonly
used for rapid tranquillization in psychotic or manic
agitation, as well as for some movement disorders
(Gillies et al. 2005). Benzodiazepines may have limited
antipsychotic and antimanic effects possibly through
inhibition of pre-synaptic release of dopamine in the
mesolimbic pathway (Gaillard et al. 2006) and they
have been found to improve some prefrontal cerebral
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functions in schizophrenia patients (Lewis et al. 2008).
However, benzodiazepines lack convincing evidence
for exerting substantial long-term antipsychotic
benefits (Bhoopathi & Soares-Weiser, 2006 ; Volz et al.
2007) in patients with schizophrenia. Benzodiazepine
treatment is also associated with adverse effects
including excessive sedation, cognitive impairment,
dependence, discontinuation or withdrawal symp-
toms including increased anxiety (Chouinard, 2004).
Adverse effects are more likely when high potency,
short half-life benzodiazepines are prescribed in
large and prolonged doses, perhaps particularly with
clozapine (Gaillard et al. 2006). There is some incon-
sistent evidence that patients with schizophrenia may
be at a lower risk of dependence (Brunette et al. 2003b ;
Wheeler et al. 2007).
Despite the apparently limited beneficial effects of
benzodiazepines in patients with schizophrenia, their
use in schizophrenia and other psychotic disorders
appears to be common in many regions of the world,
evidently mainly as non-specific, adjunctive sedatives
to supplement the effects of antipsychotics. Estimates
in the USA range from 43% (Brunette et al. 2003a, b) to
63% (Clark et al. 2004), while in Italy the estimate is
47% (Magliano et al. 2004). In China benzodiazepine
use ranges from 29.9% to 34.8% (Xiang et al. 2007a).
However, information on patterns of use, indications
and optimal dosing of benzodiazepines for schizo-
phrenia patients, and predictors of clinical response,
beneficial and adverse effects are still limited (Barnas
et al. 1993; Brunette et al. 2003b ; Fang et al. 2009;
Gorgels et al. 2006 ; Haw& Stubbs, 2007 ; Magliano et al.
2004 ; Neutel, 2005 ; Neutel et al. 2003 ; Nomura et al.
2006 ; Simon et al. 1996 ; van Hulten et al. 2003 ; Vorma
et al. 2005 ; Voshaar et al. 2003 ; Wheeler et al. 2007;
Xiang et al. 2007a). Moreover, studies of benzodiaze-
pine do not usually assess predictors of use and dose
together. Reports on adjunctive use of benzodiaze-
pines among psychotic-disorder patients in Asian
countries are particularly rare. Accordingly, we now
report on findings from an international survey study
of adjunctive use of benzodiazepines in patients diag-
nosed with schizophrenia in several Asian countries,
and sampled in 2001, 2004, and 2008.
Methods
Study design and participants
The REAP study is a pharmacoepidemiological re-
search project surveying clinical prescription practices
pertaining to psychotropic drugs for hospitalized
patients diagnosedwith schizophrenia in collaborating
Asian countries. The study began in 2001 in six Asian
countries which participated again in 2004 and 2008,
with the addition of three more countries in 2008.
Methods of case-ascertainment, diagnosis, and as-
sessment of treatments have been detailed previously
(Chong et al. 2004 ; Sim et al. 2004) and are summarized
below.
Over a 1-month period in each sampling year (2001,
2004, 2008), a random cross-sectional study was con-
ducted to yield a total of 6761 in-patients (2399, 2136,
2226 in the respective years) with schizophrenia
from the nine participating countries and regions
(PR China, Hong Kong, Japan, RO Korea, Singapore
and Taiwan in all 3 years, plus India, Thailand and
Malaysia in 2008). Uniformity of case-identification
and assessment was enhanced by regular consensus
meetings among the participants. Patient-subjects
fulfilled ICD-10 or DSM-IV diagnostic criteria for
schizophrenia at study entry as assessed by experi-
enced clinicians. Patients with clinically significant
medical illnesses or psychotic symptoms considered
secondary to substance-use disorders were excluded.
We collected and recorded information on basic
sociodemographic characteristics, clinical features, and
the identity and doses of all psychotropic medications
prescribed. Daily doses of antipsychotics, including
long-acting injected preparations, were converted
to approximate chlorpromazine-equivalents (CPZeq)
using standard guidelines (APA, 1997; Gardner et al.
2010 ; Kane et al. 1998 ; Woods, 2003) and benzodiaze-
pines similarly converted to diazepam equivalents
(DZPeq) (Ashton, 2005 ; Inagaki et al. 1999). Ratios
of prescribed vs. WHO-recommended daily doses of
each antipsychotic drug were determined as the
prescribed daily dose/daily defined dose (Tognoni,
1999 ; WHO, 2010). Ethical approval for the study was
obtained by the Institutional Review Boards of all the
participating centres.
Statistical analysis
Differences in sociodemographic and disease charac-
teristics between countries were compared using x2
(for categorical data) or ANOVA (for continuous data).
Participants were categorized into users (n=3671) vs.
non-users (n=3090) of benzodiazepines and multiple
logistic regression analysis was performed to assess
the factors associated with benzodiazepine use by
comparing the group of benzodiazepine users with
non-users. Multiple linear regression with Bonferroni
correction for multiple comparisons was performed
to assess factors associated with diazepam equiv-
alent doses in the group of participants who used
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benzodiazepines (n=3671). Malaysia was chosen as
the reference country in the multivariate analyses as
it was representative of the average percentage use
of benzodiazepines among the surveyed countries/
regions. All analysis was performed using SPSS ver-
sion 17 software (SPSS Inc., USA). Statistical signifi-
cance was set at two tailed p<0.05.
Results
Sociodemographic and clinical features (see Table 1)
The mean age of the study population (n=6761) was
43.6 years (S.D.=13.8) and the gender distribution was
58.0% (n=3863) male and 41.7% (n=2779) female.
About two thirds (65.4%) of the population were
diagnosed with schizophrenia for o10 yr. An overall
mean of 54.3% (weighted by subjects/country or re-
gion) of patients sampled received a benzodiazepine
with antipsychotic drugs. The associated antipsychotic
dose averaged 592 (S.D.=534) mg/d CPZeq. In ad-
dition to use of benzodiazepines with antipsychotics,
other adjunctive medication involved mood stabilizers
(20.4%) and antidepressants (6.8%), in addition to
prevalent use of antiparkinsonian agents (58.3%).
Patients received an average of 1.32 (S.D.=0.61) dif-
ferent benzodiazepines per person. Benzodiazepine
dosing averaged 30.3 (S.D.=32.9) mg/d DZPeq. The
top five most commonly used benzodiazepines were
lorazepamoclonazepamoflunitrazepam>>diazepam
>estazolam. These findings are summarized in Table 1.
Correlates of use of benzodiazepine as adjunctive
therapy
Taiwan and Japan had the highest rates of using ad-
junctive benzodiazepine treatment, and Thailand and
China had the least (See Fig. 1). In the multivariate
analysis, only four countries and regions (China, Hong
Kong, India, Korea) remained significantly associated
with lower benzodiazepine use.
There was a significant trend towards more use of
benzodiazepines as adjunctive therapy in 2008 com-
pared to 2004. Benzodiazepine use was greater among
patients with fewer years of illness and with current
delusions, hallucinations, disorganized speech and
social or occupational dysfunction, and was associated
with simultaneous treatment with mood stabilizers,
antiparkinsonian and antidepressant drugs, as well
as somewhat lower doses of antipsychotics. Among
adverse effects, there was less hypersalivation and
somewhat greater risk of QTc prolongation in the
electrocardiogram. Table 2 summarizes the findings
from the multivariate logistic regression analysis for
use of benzodiazepines among Asian patients with
schizophrenia.
Correlates of doses among benzodiazepines users
Patients in Thailand, Taiwan and China received the
highest total daily DZPeq doses of benzodiazepines,
and in Singapore and Korea, the lowest, with a sig-
nificant trend towards lower doses in 2008 than in
earlier years, even among the six countries sampled in
all 3 years. By multivariate modelling, only Taiwan,
China and India were associated with higher doses
and Singapore with lower doses (Table 3). Being
young, male, physically aggressive, receiving a mood
stabilizer, and having electroconvulsive therapy (ECT)
all were associated with higher doses of benzodiaze-
pines. Lower doses of benzodiazepines also were
associated with antipsychotic doses within WHO-
recommended limits. Relatively high doses of benzo-
diazepines were associated with higher risks of dry
mouth as well as amenorrhoea and galactorrhoea;
these effects may have been due to an association of
higher doses of benzodiazepines with higher doses
of antipsychotics as well as exposure to other psycho-
tropic drugs (polytherapy). Table 3 summarizes
the findings from the multivariate linear regression
analysis for dose of benzodiazepines among Asian
patients with schizophrenia.
Discussion
A main finding from this study is that adjunctive
benzodiazepine treatment of in-patients diagnosed
with DSM-IV or ICD-10 schizophrenia has been
prevalent in Asia over the past decade, averaging
54% of over 6700 schizophrenia patients sampled at
12 centres in nine countries. The most commonly used
benzodiazepines were the potent agents lorazepam
and clonazepam. Use of adjunctive benzodiazepines
was associated with prominent positive psychotic
symptoms (delusions and hallucinations), aggressive
behaviour, and occupational or social dysfunction.
Moreover, benzodiazepines also were associated
with use of other drugs, notably mood stabilizers and
antidepressants, in addition to common use of anti-
parkinsonian agents. The present findings thus add
to the impression that use of benzodiazepines as an
adjunct to antipsychotic drugs for the treatment of
psychotic-disorder patients has been about as preva-
lent in Asia as it is in many other countries (Brunette
et al. 2003a ; Clark et al. 2004 ; Haw & Stubbs, 2007 ;
Magliano et al. 2004 ; Mauri et al. 2005).
Recent guidelines for benzodiazepine use empha-
size their indication for the treatment of anxiety or
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Table 1. Characteristics of 6761 in-patients in Asian countries with schizophrenia in REAP study 2001–2008
Variable PR China Hong Kong India Japan RO Korea Singapore Taiwan Thailand Malaysia Means
Cases (n) 1524 308 181 1724 1138 491 1256 39 100 751
Men (n, %) 854 (56.0) 114 (58.4) 84 (46.4) 984 (57.1) 656 (57.6) 275 (56.0) 797 (63.5) 27 (69.2) 72 (72.0) 57.1%
Age¡S.D., yr 39.7¡13.7 42.8¡12.6 32.1¡10.8 52.3¡14.6 40.9¡10.8 44.5¡10.8 40.9¡11.1 37.7¡10.2 37.2¡10.7 43.6¡13.8 yr
BDZ use (n, %) 592 (38.9) 92 (29.9) 83 (45.9) 1190 (69.0) 522¡ (45.9) 247 (50.3) 872 (69.4) 13 (33.3) 59 (59.0) 54.3%
BDZ daily dose
(DZPeq mg¡S.D.)
40.3¡42.6 20.2¡22.5 28.0¡26.7 28.5¡22.8 15.7¡24.3 10.6¡5.90 42.0¡40.6 42.3¡28.5 18.7¡14.1 30.3¡32.9 mg
BDZ (case¡S.D.) 1.07¡0.26 1.04¡0.21 1.04¡0.20 1.63¡0.81 1.06¡0.25 1.08¡0.26 1.23¡0.44 1.00¡0.00 1.00¡0.00 1.32¡0.61/case
APD daily dose
(CPZeq mg¡S.D.)
476¡338 522¡528 482¡502 750¡712 685¡564 548¡482 493¡361 633¡332 374¡274 592¡533 mg
Years ill (%)
<1.0 10.7 1.40 23.9 3.13 3.60 2.85 1.60 6.70 10.0 5.30
1–5 21.6 12.0 32.2 6.67 11.8 9.55 10.1 20.0 19.0 12.9
5–10 14.7 16.4 22.2 8.60 23.4 23.1 18.2 20.0 32.0 16.4
>10 53.0 70.2 21.7 81.6 61.2 64.5 70.1 53.3 39.0 65.4
BDZ selections (%) Clonazepam
(20.9)
Diazepam
(11.7)
Lorazepam
(30.9)
Flunitrazepam
(37.6)
Lorazepam
(21.2)
Diazepam
(44.2)
Estazolam
(26.9)
Clonazepam
(25.6)
Lorazepam
(49.0)
Lorazepam
(12.3)
Alprazolam
(10.4)
Clonazepam
(10.7)
Clonazepam
(18.2)
Nitrazepam
(15.6)
Diazepam
(17.5)
Lorazepam
(7.54)
Clonazepam
(21.7)
Diazepam
(5.13)
Clonazepam
(7.00)
Clonazepam
(12.0)
Lorazepam
(4.66)
Lorazepam
(8.44)
Nitrazepam
(2.21)
Brotizolam
(10.8)
Clonazepam
(4.22)
Lormetazepam
(0.41)
Lorazepam
(17.1)
Lorazepam
(2.56)
Diazepam
(3.00)
Flunitrazepam
(11.4)
Estazolam
(2.56)
Flurazepam
(0.32)
– Lorazepam
(7.02)
Alprazolam
(3.43)
Clonazepam
(0.20)
Flunitrazepam
(7.88)
– – Diazepam
(8.9)
Diazepam
(0.79)
– – Etizolam
(5.63)
Flurazepam
(1.14)
– Flurazepam
(5.81)
– – Estazolam
(7.4)
APD, Antipsychotic drug; BDZ, benzodiazepine ; CPZeq, chlorpromazine-equivalent ; DZPeq, diazepam-equivalent.
Means are averages weighted by n/country or region. Ranking of five most prescribed benzodiazepines is by total percentages of use.
All differences between countries were highly significant (p<0.001) by ANOVA or x2.
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Table 2. Significant variables associated with use of benzodiazepines in Asian patients with schizophrenia from multivariate
logistic analysis
Independent variable
Use of benzodiazepines
OR (95% CI) p value
Region (reference is Malaysia)
1. PR China 0.49 (0.31–0.80) 0.004
2. Hong Kong 0.55 (0.32–0.97) 0.040
3. India 0.50 (0.29–0.87) 0.014
4. RO Korea 0.59 (0.37–0.95) 0.028
Duration of illness (reference is duration>20 yr)
5. <3 month 1.65 (1.00–2.70) 0.049
Symptoms (reference is absence of variable)
6. Delusions 1.24 (1.10–1.40) 0.001
7. Hallucinations 1.22 (1.08–1.37) 0.001
8. Disorganized speech 1.17 (1.03–1.34) 0.015
9. Social/Occupational dysfunction 1.16 (1.03–1.31) 0.016
Adverse effects (reference is absence of variable)
10. Hypersalivation 0.78 (0.64–0.95) 0.014
11. QTc prolongation 1.83 (1.10–3.04) 0.019
Other treatments (reference is absence of variable)
12. Mood stabilizer 3.15 (2.78–3.58) <0.001
13. Antiparkisonian 1.79 (1.58–2.01) <0.001
14. Antidepressant 1.33 (1.07–1.67) 0.011
15. Total chlorpromazine equivalent dosage
(units in 100 mg)
0.98 (0.97–1.00) 0.010
Year of sampling
16. 2001 0.85 (0.72–1.00) 0.043
17. 2004 0.79 (0.68–0.92) 0.002
18. 2008 Reference
OR, Odds ratio ; CI, confidence interval.
Hong Kong
Thailand
PR China
RO Korea
India
Singapore
Malaysia
Japan
Taiwan
Average
0% 10% 20% 30% 40% 50% 60% 70% 80%
Fig. 1. Rate (%) of use of benzodiazepines adjunctively with antipsychotic drugs in the treatment of hospitalized patients
diagnosed with schizophrenia in nine Asian countries, with a weighted (by n/country or region) average of 54.3%.
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insomnia, as well as for rapid sedation in acute phases
of schizophrenia or other psychotic disorders or mania
[APA, 1997; Ashton, 1994a ; FDA (Taiwan), 2009;
RACGP, 2000; RANZCP, 1999; Taylor et al. 2009].
Most guidelines do not include use of benzodiaze-
pines for chronic psychotic disorders and generally
encourage use of low doses for short periods of time,
possibly as a reflection of concern for potential abuse
and dependence of this class of central depressants
(Taylor et al. 2009).
An interesting finding from this study is that there
were distinct covariates associated with use of benzo-
diazepines and with their doses. The decision to use
benzodiazepines as an adjunctive treatment was as-
sociated with positive psychotic symptoms (delusions,
hallucinations, disorganized speech), aggressive be-
haviour, and relatively recent onset of psychotic
illness, with sufficiently severe illness as to interfere
with daily social and occupational functions. Benzo-
diazepine use also was associated with psychotropic
polytherapy, especially involving mood stabilizers,
and sometimes antidepressants and ECT, and higher
doses were more common among aggressive, young,
male patients. These associations, taken together,
suggest that benzodiazepines were being used for
additional sedative effects among particularly difficult
to treat psychotic patients.
We propose that more specific guidelines for
adjunctive use of benzodiazepines in schizophrenia
be developed, including considerations that may be
specific to particular Asian countries, which varied
substantially in the use and doses of benzodiazepines.
The multivariate analysis showed that use of benzo-
diazepines was lower in PR China and Hong Kong,
possibly because of strict governmental regulation and
accounting of benzodiazepines and public education
Table 3. Significant variables associated with dose of benzodiazepines in Asian patients with schizophrenia from multivariate
linear regression analysis
Independent variable
Dose of benzodiazepines
Slope (b) (95% CI) p value
Region (reference is Malaysia)
1. PR China 15.3 (6.53 to 24.0) 0.001
2. India 10.4 (0.04 to 20.8) 0.049
3. Singapore x11.5 (x20.4 tox2.5) 0.012
4. Taiwan 18.8 (10.4 to 27.2) <0.001
Demographics
5. Age (yr) x0.11 (x0.213 tox0.002) 0.046
6. Male (Reference is female) 3.07 (1.00 to 5.12) 0.004
Duration of illness (reference is duration>20 yr)
7. 6–12 month x8.63 (x15.8 tox1.47) 0.018
8. 5–10 years x3.91 (x7.34 tox0.48) 0.025
Symptoms (reference is absence of variable)
9. Physical aggression 4.00 (0.65 to 7.36) 0.019
Adverse effects (reference is absence of variable)
10. Dry mouth 3.07 (0.29 to 5.85) 0.031
11. Amenorrhoea, galactorrhoea 8.55 (2.33 to 14.8) 0.007
Other treatments (reference is absence of variable)
12. Mood stabilizer 17.4 (15.3 to 19.5) <0.001
13. ECT 10.4 (4.35 to 16.4) 0.001
14. Meets WHO APD dosing guidelines
(reference is exceeding guidelines)
x5.48 (x9.59 tox1.36) 0.009
Year of sampling
15. 2001 3.50 (0.69 to 6.25) 0.015
16. 2004 2.72 (0.07 to 5.36) 0.044
17. 2008 Reference
CI, Confidence interval.
p value of statistical significance with Bonferroni correction.
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of the their potential adverse effects in that country.
The lower use of benzodiazepines in PR China and
Hong Kong could also be related to the relatively high
use of clozapine (62% and 34%, respectively) in
patients with schizophrenia (Chong et al. 2004) and
long duration of illness (53% and 70%, respectively of
patients ill for >10 yr) that decreases the need for
additional sedation. The lower doses of benzodiaze-
pines in Singapore could be related to the adoption of
guidelines for recommended drug doses within the
psychiatric hospital and their strict government en-
forcement. Similarly, governmental regulation could
also account for the higher doses of benzodiazepines
in Taiwan as in recent years there has been a national
database to track benzodiazepine use and prevent
‘doctor shopping’ by patients and over-prescription of
benzodiazepines. The prescription of any psycho-
tropic medication is ultimately a result of a myriad of
interactional factors including patient, prescriber and
practice setting factors (Shinfuku&Tan, 2008 ; Tan et al.
2008 ; Xiang et al. 2007b), that change rapidly over time
(An et al. 2010 ; Mojtabai & Olfson, 2010) and are un-
likely to be attributable to any single aspect. Further
studies are needed to elucidate prescriber attitudes
towards the administration of specific medications
including benzodiazepines and relevant pharmaco-
economic issues which can affect prescription pat-
terns. Dosing of benzodiazepines in many countries,
including in Asia, has often followed guidelines from
the USA (APA, 1997) or Europe (Taylor et al. 2009), as
specific guidelines for the use of psychotropic drugs
for Asian populations remain rare [FDA (Taiwan),
2009]. Although the proportion of schizophrenia
patients given adjunctive benzodiazepines in the
present Asian samples is similar to that reported in
Western countries (Clark et al. 2004 ; Magliano et al.
2004 ; Neutel, 2005), there is some indication that
the metabolic clearance of benzodiazepines may be
less rapid among Asians than Caucasians, with corre-
spondingly higher peak plasma concentrations per
dose (Bond, 1991 ; Chen, 2006). Nevertheless, it is
likely that regional variance in the adjunctive use of
benzodiazepines and their dosing reflects the influ-
ence of local prescribing practices in Asia (Bitter et al.
2003 ; Lai et al. 2009 ; Nakao et al. 2007 ; Xiang et al.
2007a) as in other parts of theworld (Dunbar et al. 1989;
Ekedahl et al. 1993 ; Hermos et al. 2005 ; Isacson,
1997 ; Neutel, 2005 ; Petitjean et al. 2007 ; Ruiz et al.
1993 ; Valenstein et al. 2004).
A major predictor for both increased use and higher
doses of benzodiazepines is the simultaneous use
of mood stabilizers along with antipsychotic drugs
(polytherapy). There is little evidence that Asian
patients diagnosed with schizophrenia have un-
usually prominent mood disturbances, although mis-
diagnosis of schizoaffective disorders, psychotic mood
disorders, or bipolar disorder, or the presence of
comorbid anxiety disorders, can occur in chronically
psychotic patients (Averill et al. 2004 ; Chen et al. 1998;
Salvatore et al. 2009 ; Smith et al. 1992 ; Subramaniam
et al. 2007). Diagnoses of most psychotic disorders by
either DSM-IV or ICD-10 criteria (Salvatore et al. 2009,
in press) may not be stable over time. Such factors, as
well as the irritability and aggressive behaviour found
in association with adjunctive treatment in this study,
may contribute to use of mood stabilizers as well as
benzodiazepines with antipsychotic drugs (Bobes et al.
2009 ; Centorrino et al. 2010 ; Joyal et al. 2008 ; Magliano
et al. 2004 ; Swanson et al. 2006). In general, it seems
especially likely that benzodiazepines were used
largely in a non-specific manner, as relatively well-
tolerated central depressants and sedatives, to address
unsatisfactory responses or lack of tolerance of stan-
dard antipsychotic drug therapy (Basan et al. 2004 ;
Citrome, 2009).
The apparently increased risk of certain adverse
effects associated with adjunctive benzodiazepine
treatment is noteworthy, as detailed above. There
were unexpected associations with higher risk of QTc
prolongation, as well as more dry mouth, amenor-
rhoea and galactorrhoea, but less hypersalivation
during benzodiazepine treatment, especially at higher
doses. Many of these adverse effects are associated
with antipsychotic drugs, and are less likely to be
attributable to benzodiazepines (Taylor et al. 2009).
There is some evidence that benzodiazepines use, es-
pecially with other drugs, can increase risk of slowed
cardiac repolarization (QTc prolongation) (Baranchuk
et al. 2008 ; Kato et al. 2009 ; Yamagiwa et al. 2010 ;
Ziegenbein & Kropp, 2004) although this association is
not unequivocal (Crockford, 2005; Goodnick et al.
2002). However the evidence that benzodiazepines
can contribute to amenorrhoea and galactorrhoea
(presumably via hyperprolactinaemia) is more robust
(Hussain et al. 1972 ; Shioiri et al. 1996 ; Tkachenko et al.
1984), especially for higher doses of benzodiazepine
(Weizman et al. 1984) and in combination with anti-
psychotics (Bondolfi et al. 1997 ; Kopecek et al. 2006).
It seems prudent to warn patients of these uncommon
side-effects of benzodiazepines, especially when they
are given in high doses and with other psychotropic
medicines for patients with schizophrenia.
There was a curious pattern of simultaneous in-
creasing use and decreasing dose of benzodiazepines
in second and third waves of the REAP study.
Benzodiazepines are indicated for the treatment of
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anxiety, insomnia and for rapid tranquillization
in schizophrenia [APA, 1997; Ashton, 1994a ; FDA
(Taiwan), 2009 ; RACGP, 2000; RANZCP, 1999; Taylor
et al. 2009]. Their use adjunctively with antipsychotic
drugs to treat chronically psychotic patients without a
great deal of backing from research or practice guide-
lines may have encouraged clinicians to be cautious
in their dosing of benzodiazepines in such circum-
stances, but to select them to counter such symptoms
as anxiety, insomnia, agitation, or aggression, as well
as to limit doses of antipsychotics.
Study limitations
This study involved only 1-month samples from 3 yr
of the past decade, small numbers of patients in some
sites, lack of control of potential sources of hetero-
geneity across sites, and was limited to hospitalized
patients diagnosed with schizophrenia by one of
two standard international diagnostic systems, and to
single assessments. Moreover, as a cross-sectional
survey study, it was limited in its ability to explore
associations among benzodiazepine use and dose with
beneficial or adverse effects over time, and relation-
ships to sociodemographic variables and both current
and past clinical details. The interpretation of some
statistically significant associations should therefore
be made with caution, and conservatively applied
with Bonferroni corrections.
Conclusion
Adjunctive benzodiazepine treatment of Asian
patients diagnosed with schizophrenia was common
over the past decade, and use of such treatment and
doses varied substantially between countries. Adjun-
ctive benzodiazepine treatment was more prevalent
among patients with positive psychotic symptoms or
aggressive behaviours, and was often encountered
with use of polytherapy. These associations suggest
that this and perhaps use of other adjuncts to anti-
psychotic drugs reflects the relative severity of psy-
chotic illnesses that do not respond adequately to
standard antipsychotic treatment alone, or when anti-
psychotics are not well tolerated, especially in high
doses. Finally, we recommend that critical clinical
guidelines be developed specifically for Asian coun-
tries to address sound practices in regard to use of
benzodiazepines for psychotic disorders, as well as for
other aspects of treatment with psychotropic drugs.
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